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The term ‘myelopathy’ is used in this brief 
critical communication in preference to the 
commonly used term ‘myelitis’ to highlight 
that all cases of acute transverse myelopa-
thies are not of inﬂ  ammatory  origin. 
Indeed metabolic and vascular myelopa-
thies, at times, do pose serious diagnostic 
problems and need different therapeutic 
approaches.
The ﬁ  rst question, when faced with a 
clinically obvious transverse myelopathy, 
is whether it is really a ‘new’ ‘acute’ onset 
disease or an ‘acute’ exacerbation of a pre-
existing unsuspected or unknown com-
pressive or non-compressive myelopathic 
problem or perhaps a super addition of an 
acute non-compressive pathology on top of 
a mild pre-existing compressive problem. 
This issue needs to be settled at the very out-
set by careful history elicitation including 
family history and a very thorough neuro-
radiological assessment. It must be stressed 
that spinal MRI must involve the entire 
spine with contrast and not limited only to 
the clinically suggestive level, not only to 
exclude unsuspected compressive pathology 
elsewhere but also to gauge the full length 
of the detected spinal lesion and exclude 
multiplicity of similar lesions elsewhere in 
the spinal cord. Even after careful radio-
logical study, it may be sometimes difﬁ  cult 
to differentiate inﬂ  ammatory lesions from 
intramedullary tumors, subtle extramedul-
lary spinal cord compression with marked 
signal changes in the spinal cord at the same 
level or even extending above and below the 
level including hematoma and/or ischemic 
events. Imaging should preferably include 
the brain as well if an inﬂ  ammatory process 
is suspected. Establishing the etiology must 
also include cerebrospinal ﬂ  uid (CSF) anal-
ysis with immunological studies. Two recent 
reviews by Brinar et al. (2008) and Jacob 
and Weinshenker (2008) detail the differ-
ential diagnosis and of acute transverse 
myelopathies. The latter workers (Jacob and 
Weinshenker, 2008) have presented a very 
clinically oriented approach to ﬁ  nding the 
etiology based on anatomical   localization 
of region of cord affected as revealed by 
thorough clinical and radiological means. 
They have classiﬁ  ed all intrinsic cord syn-
dromes as – complete, Brown-Séquard syn-
drome, anterior cord syndrome, posterior 
cord syndrome, central cord syndrome, 
conus medullaris syndrome, cauda equina 
syndrome, and tractopathies. This appears 
to be an excellent approach. These authors 
(Jacob and Weinshenker, 2008) have also 
provided a ‘ﬂ  ow chart’ approach to mye-
lopathies which seems to be very useful for 
the practicing clinician.
Acute inﬂ  ammatory myelopathies can 
not solely be due to established autoimmune 
central nervous system (CNS) demyelinat-
ing disorders of CNS like multiple sclerosis 
(MS), acute disseminated encephalomyelitis 
(ADEM) or neuromyelitis optica (NMO), 
but may also complicate several systemic 
autoimmune disorders including systemic 
lupus erythematosus (SLE), Sjogren’s syn-
drome, antiphospholipid antibody syn-
drome, mixed connective tissue disease, 
systemic sclerosis, ankylosing spondylitis 
and sarcoidosis.
The talk of the day is of course the 
discovery of the Aquaporin4 antibody 
(NMO-IgG), a hallmark of the NMO spec-
trum disorders with long segment spinal 
cord signal changes with or without optic 
nerve involvement. NMO is now gener-
ally regarded as quite distinct from MS as 
the prognosis and radiology are somewhat 
different. However, the antibody may also 
be detected in some cases of classical MS 
and may be undetectable in as high as 30% 
cases of classical NMO. NMO-IgG anti-
body is not simply a diagnostic marker but 
has a pathological bearing. This represents 
a unique dysfunction of water channels 
which has been linked to the spinal cord 
edema in NMO with intact blood brain 
barrier (no GAD enhancement) and this 
helps in differentiation from spinal lesion 
in ADEM (GAD enhancing). Earlier work-
ers from Japan and India pointed out at the 
long segment spinal lesions (three segments 
or more) in Asian patients with MS. These 
studies were done before the publication of 
the revised McDonald (Polman et al., 2005) 
criteria for diagnosis of MS and before the 
availability of the NMO-IgG antibody test. 
It is essential to review such cases both in 
terms of the current diagnostic criteria of 
MS as well as presence or absence of the 
antibody in the CSF. The wider availabil-
ity of the antibody test and at a lesser cost 
in developing Asian countries need not be 
overemphasized.
A major clinical problem arises in 
patients with clinical features of a trans-
verse myelopathy associated with a normal 
spinal MRI. The ﬁ  rst thing would be to 
go back on clinical details to make sure 
whether it was indeed a myelopathy and 
not an atypical presentation of a peripheral 
neuropathic lesion (like Guillain-Barré 
syndrome) or a rare presentation of a cer-
ebral pathology. The second would be a 
careful review of the whole spine contrast 
enhanced MRI and if needed, a repeat 
MRI. Having done so, the CSF needs care-
ful examination. This might show the pres-
ence of oligoclonal bands or a raised CSF 
protein content but no vigorous inﬂ  am-
matory response. These along with the lack 
of radiologically demonstrable demyelina-
tion, might suggest that parenchymatous 
neurons are the sites of pathologic involve-
ment, analogous to the acute lesions of 
axonal polyneuropathy. Such cases would 
be variants of ADEM although similar 
cases had been described in patients with 
SLE and regarded as part of the NMO spec-
trum (Jacobi et al., 2006).
The ﬁ  nal and essential challenge is assess-
ment of risk of recurrence. Complete trans-
verse myelitis patients in general are at low 
risk of future development of MS. However, 
they could have recurrences consistent with 
relapsing myelitis or NMO. Two immune 
markers that may predict recurrence are 
anti-Sjögren syndrome antibody (SS-A) and 
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studied and is a must in all cases of trans-
verse myelopathies. Patients with incom-
plete transverse myelitis, on the other hand 
can be considered to have clinically isolated 
forms of MS (CIS) and the risk of future 
development of MS would remain a worry. 
When associated with brain lesions the risk 
is high (over 80%), but with no associated 
brain lesions the risk is relatively low (less 
than 20%). The diagnosis of acute infec-
tive myelitis, radiation myelopathies and 
paraneoplastic acute myelopathies, are rela-
tively simple. Diagnosing the latter however, 
demands strong clinical suspicion, thorough 
clinical and radiological search for hidden 
neoplasia coupled with testing for a wide 
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variety of paraneoplastic antibodies in cases 
where the cause of an acute non-compressive 
transverse myelopathy is not apparent.
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